|
Fusion Gene Summary | |
Fusion Gene ORF analysis | |
Fusion Genomic Features | |
Fusion Protein Features | |
Fusion Gene Sequence | |
Fusion Gene PPI analysis | |
Related Drugs | |
Related Diseases |
Fusion gene:FRMD3-NTRK2 (FusionGDB2 ID:HG257019TG4915) |
Fusion Gene Summary for FRMD3-NTRK2 |
Fusion gene summary |
Fusion gene information | Fusion gene name: FRMD3-NTRK2 | Fusion gene ID: hg257019tg4915 | Hgene | Tgene | Gene symbol | FRMD3 | NTRK2 | Gene ID | 257019 | 4915 |
Gene name | FERM domain containing 3 | neurotrophic receptor tyrosine kinase 2 | |
Synonyms | 4.1O|EPB41L4O|EPB41LO|P410 | EIEE58|GP145-TrkB|OBHD|TRKB|trk-B | |
Cytomap | ('FRMD3')('NTRK2') 9q21.32 | 9q21.33 | |
Type of gene | protein-coding | protein-coding | |
Description | FERM domain-containing protein 3band 4.1-like protein 4band 4.1-like protein 4Oovary type protein 4.1protein 4.1O | BDNF/NT-3 growth factors receptorBDNF-tropomyosine receptor kinase Bneurotrophic tyrosine kinase receptor type 2tropomyosin-related kinase Btyrosine kinase receptor B | |
Modification date | 20200313 | 20200313 | |
UniProtAcc | . | Q16620 | |
Ensembl transtripts involved in fusion gene | ENST00000304195, ENST00000376438, ENST00000328788, ENST00000376434, ENST00000465485, | ||
Fusion gene scores | * DoF score | 5 X 5 X 5=125 | 10 X 9 X 7=630 |
# samples | 5 | 10 | |
** MAII score | log2(5/125*10)=-1.32192809488736 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(10/630*10)=-2.65535182861255 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: FRMD3 [Title/Abstract] AND NTRK2 [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | FRMD3(86152999)-NTRK2(87482157), # samples:1 | ||
Anticipated loss of major functional domain due to fusion event. | FRMD3-NTRK2 seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. FRMD3-NTRK2 seems lost the major protein functional domain in Tgene partner, which is a kinase due to the frame-shifted ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Fusion gene information * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerDB4 | THCA | TCGA-ET-A39T | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
Top |
Fusion Gene ORF analysis for FRMD3-NTRK2 |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
5CDS-intron | ENST00000304195 | ENST00000277120 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
5CDS-intron | ENST00000304195 | ENST00000304053 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
5CDS-intron | ENST00000304195 | ENST00000323115 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
5CDS-intron | ENST00000304195 | ENST00000359847 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
5CDS-intron | ENST00000304195 | ENST00000376208 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
5CDS-intron | ENST00000304195 | ENST00000395866 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
5CDS-intron | ENST00000304195 | ENST00000395882 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
5CDS-intron | ENST00000376438 | ENST00000277120 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
5CDS-intron | ENST00000376438 | ENST00000304053 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
5CDS-intron | ENST00000376438 | ENST00000323115 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
5CDS-intron | ENST00000376438 | ENST00000359847 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
5CDS-intron | ENST00000376438 | ENST00000376208 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
5CDS-intron | ENST00000376438 | ENST00000395866 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
5CDS-intron | ENST00000376438 | ENST00000395882 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
Frame-shift | ENST00000304195 | ENST00000376213 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
Frame-shift | ENST00000304195 | ENST00000376214 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
Frame-shift | ENST00000376438 | ENST00000376213 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
Frame-shift | ENST00000376438 | ENST00000376214 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
intron-3CDS | ENST00000328788 | ENST00000376213 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
intron-3CDS | ENST00000328788 | ENST00000376214 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
intron-3CDS | ENST00000376434 | ENST00000376213 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
intron-3CDS | ENST00000376434 | ENST00000376214 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
intron-3CDS | ENST00000465485 | ENST00000376213 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
intron-3CDS | ENST00000465485 | ENST00000376214 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
intron-intron | ENST00000328788 | ENST00000277120 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
intron-intron | ENST00000328788 | ENST00000304053 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
intron-intron | ENST00000328788 | ENST00000323115 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
intron-intron | ENST00000328788 | ENST00000359847 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
intron-intron | ENST00000328788 | ENST00000376208 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
intron-intron | ENST00000328788 | ENST00000395866 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
intron-intron | ENST00000328788 | ENST00000395882 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
intron-intron | ENST00000376434 | ENST00000277120 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
intron-intron | ENST00000376434 | ENST00000304053 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
intron-intron | ENST00000376434 | ENST00000323115 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
intron-intron | ENST00000376434 | ENST00000359847 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
intron-intron | ENST00000376434 | ENST00000376208 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
intron-intron | ENST00000376434 | ENST00000395866 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
intron-intron | ENST00000376434 | ENST00000395882 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
intron-intron | ENST00000465485 | ENST00000277120 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
intron-intron | ENST00000465485 | ENST00000304053 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
intron-intron | ENST00000465485 | ENST00000323115 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
intron-intron | ENST00000465485 | ENST00000359847 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
intron-intron | ENST00000465485 | ENST00000376208 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
intron-intron | ENST00000465485 | ENST00000395866 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
intron-intron | ENST00000465485 | ENST00000395882 | FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + |
ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for FRMD3-NTRK2 |
FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + | 2.52E-06 | 0.9999975 |
FRMD3 | chr9 | 86152999 | - | NTRK2 | chr9 | 87482157 | + | 2.52E-06 | 0.9999975 |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for FRMD3-NTRK2 |
Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:86152999/:87482157) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
. | NTRK2 |
FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}. | FUNCTION: Receptor tyrosine kinase involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity (By similarity). Receptor for BDNF/brain-derived neurotrophic factor and NTF4/neurotrophin-4. Alternatively can also bind NTF3/neurotrophin-3 which is less efficient in activating the receptor but regulates neuron survival through NTRK2 (PubMed:7574684, PubMed:15494731). Upon ligand-binding, undergoes homodimerization, autophosphorylation and activation (PubMed:15494731). Recruits, phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades. Through SHC1, FRS2, SH2B1, SH2B2 activates the GRB2-Ras-MAPK cascade that regulates for instance neuronal differentiation including neurite outgrowth. Through the same effectors controls the Ras-PI3 kinase-AKT1 signaling cascade that mainly regulates growth and survival. Through PLCG1 and the downstream protein kinase C-regulated pathways controls synaptic plasticity. Thereby, plays a role in learning and memory by regulating both short term synaptic function and long-term potentiation. PLCG1 also leads to NF-Kappa-B activation and the transcription of genes involved in cell survival. Hence, it is able to suppress anoikis, the apoptosis resulting from loss of cell-matrix interactions. May also play a role in neutrophin-dependent calcium signaling in glial cells and mediate communication between neurons and glia. {ECO:0000250|UniProtKB:P15209, ECO:0000269|PubMed:15494731, ECO:0000269|PubMed:7574684}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for FRMD3-NTRK2 |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for FRMD3-NTRK2 |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for FRMD3-NTRK2 |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Tgene | NTRK2 | Q16620 | DB00321 | Amitriptyline | Agonist | Small molecule | Approved |
Tgene | NTRK2 | Q16620 | DB00321 | Amitriptyline | Agonist | Small molecule | Approved |
Tgene | NTRK2 | Q16620 | DB11823 | Esketamine | Small molecule | Approved|Investigational | |
Tgene | NTRK2 | Q16620 | DB11823 | Esketamine | Small molecule | Approved|Investigational | |
Tgene | NTRK2 | Q16620 | DB11986 | Entrectinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | NTRK2 | Q16620 | DB11986 | Entrectinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | NTRK2 | Q16620 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | NTRK2 | Q16620 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | NTRK2 | Q16620 | DB14723 | Larotrectinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | NTRK2 | Q16620 | DB14723 | Larotrectinib | Inhibitor | Small molecule | Approved|Investigational |
Top |
Related Diseases for FRMD3-NTRK2 |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | FRMD3 | C0263454 | Chloracne | 1 | CTD_human |
Tgene | C0011570 | Mental Depression | 5 | PSYGENET | |
Tgene | C0011581 | Depressive disorder | 5 | PSYGENET | |
Tgene | C0041696 | Unipolar Depression | 5 | PSYGENET | |
Tgene | C0525045 | Mood Disorders | 5 | PSYGENET | |
Tgene | C1269683 | Major Depressive Disorder | 5 | PSYGENET | |
Tgene | C3151303 | Obesity, Hyperphagia, and Developmental Delay | 4 | CTD_human;GENOMICS_ENGLAND;UNIPROT | |
Tgene | C0005586 | Bipolar Disorder | 3 | CTD_human;PSYGENET | |
Tgene | C4693367 | EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 58 | 3 | GENOMICS_ENGLAND;UNIPROT | |
Tgene | C0009171 | Cocaine Abuse | 2 | CTD_human | |
Tgene | C0036341 | Schizophrenia | 2 | PSYGENET | |
Tgene | C0038220 | Status Epilepticus | 2 | CTD_human | |
Tgene | C0236736 | Cocaine-Related Disorders | 2 | CTD_human | |
Tgene | C0270823 | Petit mal status | 2 | CTD_human | |
Tgene | C0311335 | Grand Mal Status Epilepticus | 2 | CTD_human | |
Tgene | C0393734 | Complex Partial Status Epilepticus | 2 | CTD_human | |
Tgene | C0600427 | Cocaine Dependence | 2 | CTD_human | |
Tgene | C0751217 | Hyperkinesia, Generalized | 2 | CTD_human | |
Tgene | C0751522 | Status Epilepticus, Subclinical | 2 | CTD_human | |
Tgene | C0751523 | Non-Convulsive Status Epilepticus | 2 | CTD_human | |
Tgene | C0751524 | Simple Partial Status Epilepticus | 2 | CTD_human | |
Tgene | C3887506 | Hyperkinesia | 2 | CTD_human | |
Tgene | C0001973 | Alcoholic Intoxication, Chronic | 1 | PSYGENET | |
Tgene | C0004114 | Astrocytoma | 1 | CTD_human | |
Tgene | C0004352 | Autistic Disorder | 1 | CTD_human | |
Tgene | C0005587 | Depression, Bipolar | 1 | CTD_human | |
Tgene | C0008073 | Developmental Disabilities | 1 | CTD_human | |
Tgene | C0013415 | Dysthymic Disorder | 1 | PSYGENET | |
Tgene | C0017638 | Glioma | 1 | CTD_human | |
Tgene | C0020505 | Hyperphagia | 1 | CTD_human | |
Tgene | C0024713 | Manic Disorder | 1 | CTD_human | |
Tgene | C0027819 | Neuroblastoma | 1 | CTD_human | |
Tgene | C0028754 | Obesity | 1 | CTD_human | |
Tgene | C0036349 | Paranoid Schizophrenia | 1 | PSYGENET | |
Tgene | C0037769 | West Syndrome | 1 | ORPHANET | |
Tgene | C0085996 | Child Development Deviations | 1 | CTD_human | |
Tgene | C0085997 | Child Development Disorders, Specific | 1 | CTD_human | |
Tgene | C0205768 | Subependymal Giant Cell Astrocytoma | 1 | CTD_human | |
Tgene | C0259783 | mixed gliomas | 1 | CTD_human | |
Tgene | C0280783 | Juvenile Pilocytic Astrocytoma | 1 | CTD_human | |
Tgene | C0280785 | Diffuse Astrocytoma | 1 | CTD_human | |
Tgene | C0334579 | Anaplastic astrocytoma | 1 | CTD_human | |
Tgene | C0334580 | Protoplasmic astrocytoma | 1 | CTD_human | |
Tgene | C0334581 | Gemistocytic astrocytoma | 1 | CTD_human | |
Tgene | C0334582 | Fibrillary Astrocytoma | 1 | CTD_human | |
Tgene | C0334583 | Pilocytic Astrocytoma | 1 | CTD_human | |
Tgene | C0338070 | Childhood Cerebral Astrocytoma | 1 | CTD_human | |
Tgene | C0338831 | Manic | 1 | CTD_human | |
Tgene | C0547065 | Mixed oligoastrocytoma | 1 | CTD_human | |
Tgene | C0555198 | Malignant Glioma | 1 | CTD_human | |
Tgene | C0678807 | prenatal alcohol exposure | 1 | PSYGENET | |
Tgene | C0750935 | Cerebral Astrocytoma | 1 | CTD_human | |
Tgene | C0750936 | Intracranial Astrocytoma | 1 | CTD_human | |
Tgene | C0752347 | Lewy Body Disease | 1 | CTD_human | |
Tgene | C1519086 | Pilomyxoid astrocytoma | 1 | ORPHANET | |
Tgene | C1704230 | Grade I Astrocytoma | 1 | CTD_human | |
Tgene | C3146244 | Alcohol Related Birth Defect | 1 | PSYGENET |